Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program
- None.
- None.
— Competitive Grant Program to Offer Individual Grants of Up to
— Application Period to Run From Sept. 15, 2023 Through Nov. 30, 2023 —
"Great science is the foundation for everything we do at Alkermes, and our support for these innovative research projects is an extension of that commitment," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes. "As the Pathways program continues to evolve, we are proud of its impact to date in supporting the work of early-career researchers dedicated to making progress on behalf of people living with complex diseases like schizophrenia and bipolar disorder."
The 6th annual Alkermes Pathways Research Awards program will offer grants in amounts of up to
The Pathways program began in 2018 and has since provided approximately
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in
Alkermes Pathways Research Awards® is a registered service mark of Alkermes, Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc.
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Gretchen Murphy, +1 781 609 6419
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-launch-of-6th-annual-alkermes-pathways-research-awards-program-301919852.html
SOURCE Alkermes plc
FAQ
What is Alkermes plc (Nasdaq: ALKS) announcing?
When is the application period for the Alkermes Pathways Research Awards program?
Who is eligible for the grants?
How much funding has the Pathways program provided since its inception?